<DOC>
	<DOCNO>NCT02466399</DOCNO>
	<brief_summary>This open-label , randomize , multi-center , active-controlled parallel-comparison POLAT-001 latanoprost ophthalmic solution patient ocular hypertension primary open-angle glaucoma .</brief_summary>
	<brief_title>POLAT-001 Compared Latanoprost Ophthalmic Solution Patients With Ocular Hypertension Open-angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . 18 year age great . 2 . Diagnosis primary open angle glaucoma ( OAG ) ocular hypertension ( OHT ) . 3 . Unmedicated ( postwashout ) intraocular pressure ( IOP ) ≥ 24 mm Hg 2 eligibility visit ( 0800 hr ) , 27 day apart . If eyes meet IOP criterion , eye high IOP Visit 1 designate study eye . If IOP eye , right eye designate study eye . Note eyes treat . 4 . Corrected visual acuity Visit 1 eye +1.0 logarithm minimum angle resolution ( logMAR ) good Early Treatment Diabetic Retinopathy Study ( ETDRS ) eye ( equivalent 20/200 ) . 5 . Able willing give sign informed consent follow study instruction . 6 . Subjects must document history ≥ 20 % IOP reduction O.U . use topical ocular prostaglandin/prostamide ocular hypotensive medication . Ophthalmic 1 . Glaucoma : pseudoexfoliation pigment dispersion component , history angle closure narrow angle judge occludable investigator . Note : Previous laser peripheral iridotomy NOT acceptable . 2 . IOP &gt; 36 mm Hg either eye prerandomization study visit . 3 . Known corticosteroidresponder judge investigator . 4 . Known hypersensitivity component Investigational Product formulation ( benzalkonium chloride , etc . ) , fluoroquinolone ophthalmic solution , topical anesthetic , Povidone Iodine antiseptic , diagnostic eye drop . 5 . Previous glaucoma intraocular surgery glaucoma laser procedures either eye . 6 . Refractive surgery either eye . 7 . Ocular trauma , extraocular intraocular surgery laser treatment within past six month either eye . 8 . Evidence ocular infection , inflammation , clinically significant blepharitis conjunctivitis baseline ( Visit 1 ) , history herpes simplex keratitis either eye . Note : mild blepharitis , allergy dry eye acceptable . 9 . Ocular medication kind within 30 day Visit 1 either eye , exception ) ocular hypotensive therapy ( must wash accord provided schedule ) , b ) lid scrub ( may use prior , Visit 1 ) c ) lubricate drop dry eye ( may use throughout study ) . 10 . Clinically significant ocular disease ( e.g . uveitis , severe keratoconjunctivitis sicca ) either eye might interfere study , include glaucomatous damage severe washout ocular hypotensive medication one month judge safe investigator ( i.e. , cupdisc ratio &gt; 0.8 ) . 11 . Central corneal thickness great 600 µm either eye . 12 . Any ocular abnormality prevent reliable applanation tonometry either eye . 13 . Significant medium opacity either eye would exclude adequate posterior segment examination 14 . Contraindications pupil dilation either eye . 15 . Unwillingness accept known adverse event latanoprost eyelid and/or iris pigmentation , eyelash growth , etc . 16 . History macular edema , include cystoid macular edema , current recent ( 6 month ) uveitis . 17 . Planned intraocular surgery either eye study participation Systemic : 18 . Clinically significant abnormality ( determine treat physician ) laboratory test screen . 19 . Known hypersensitivity systemic contraindication latanoprost component study medication . 20 . Clinically significant systemic disease ( e.g. , myasthenia gravis , hepatic , renal , endocrine cardiovascular disorder ) , might interfere study . 21 . Participation investigational study within 30 day prior baseline . 22 . Changes systemic medication could substantial effect IOP within 30 day prior screen , anticipate study . 23 . Any individual investigator believe might suffer physical mental harm participate trial . Due current status preclinical safety program , woman childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine pregnancy test result Visit 1 examination must agree use acceptable method contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>